What this means
This study plans to check safety and early effects of two options against a placebo group. It has not started and has no results yet, so it cannot show whether either option works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 45–65
- Where
- 1 site, including California
The science
- Registered title
- A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
- Trial ID
- NCT06682767 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- Cerebral Blood Flow, APOE 4
- What is tested
- FMD1 (LNT22-017-1), Rapamycin, Placebo
- Sponsor
- Cedars-Sinai Medical Center
- Ages
- 45 Years to 65 Years
- Dates
- First posted Nov 12, 2024 · updated Sep 16, 2026
Registry summary
The study aims to evaluate the safety, feasibility, and preliminary efficacy of the fasting-mimicking diet (FMD) or low-dose daily rapamycin treatment relative to a matched placebo control group when administered over 8 weeks in middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele. Participants randomly assigned to the FMD intervention will adhere to FMD for 5-days over three cycles for a period of approximately 8 weeks. Participants randomly assigned to the rapamycin and placebo groups will take 1 mg of rapamycin or a matched placebo pill daily for approximately 8 weeks.
Sites (1)
- Cedars Sinai Medical Center, Los Angeles, California, United States